GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regenetp Inc (STU:NJT) » Definitions » Cyclically Adjusted PS Ratio

Regenetp (STU:NJT) Cyclically Adjusted PS Ratio : (As of Jun. 07, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Regenetp Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Regenetp Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Regenetp's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regenetp Cyclically Adjusted PS Ratio Chart

Regenetp Annual Data
Trend Oct13 Oct14 Oct15 Oct16 Oct17 Oct18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.20 0.04 0.01 0.02 -

Regenetp Quarterly Data
Apr18 Jul18 Oct18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 - - - -

Competitive Comparison of Regenetp's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Regenetp's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regenetp's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regenetp's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Regenetp's Cyclically Adjusted PS Ratio falls into.



Regenetp Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Regenetp's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2023 is calculated as:

For example, Regenetp's adjusted Revenue per Share data for the three months ended in Mar. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2023 (Change)*Current CPI (Mar. 2023)
=0/127.3478*127.3478
=0.000

Current CPI (Mar. 2023) = 127.3478.

Regenetp Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201304 191.410 98.107 248.459
201307 78.308 98.557 101.184
201310 171.767 98.536 221.993
201401 374.419 98.692 483.135
201404 54.558 100.023 69.462
201407 52.463 100.520 66.465
201410 115.279 100.176 146.548
201501 69.512 98.604 89.776
201504 35.795 99.824 45.665
201507 19.077 100.691 24.127
201510 5.135 100.346 6.517
201601 8.119 99.957 10.344
201604 4.840 100.947 6.106
201607 0.000 101.524 0.000
201610 0.000 101.988 0.000
201701 0.000 102.456 0.000
201704 0.000 103.167 0.000
201707 0.000 103.278 0.000
201710 0.000 104.070 0.000
201801 0.042 104.578 0.051
201804 0.004 105.708 0.005
201807 0.443 106.324 0.531
201810 1.156 106.695 1.380
201903 1.501 107.251 1.782
201906 1.185 108.070 1.396
201909 1.200 108.329 1.411
201912 1.219 108.420 1.432
202003 0.639 108.902 0.747
202006 1.309 108.767 1.533
202009 1.828 109.815 2.120
202012 1.561 109.897 1.809
202103 1.295 111.754 1.476
202106 0.649 114.631 0.721
202109 0.290 115.734 0.319
202112 0.281 117.630 0.304
202203 0.188 121.301 0.197
202206 0.013 125.017 0.013
202209 0.000 125.227 0.000
202212 0.000 125.222 0.000
202303 0.000 127.348 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Regenetp  (STU:NJT) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Regenetp Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Regenetp's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Regenetp (STU:NJT) Business Description

Industry
Traded in Other Exchanges
Address
1960 South 4250 West, Salt Lake City, UT, USA, 84104
Regenetp Inc Formerly PolarityTE Inc is a clinical-stage biotechnology company developing regenerative tissue products and biomaterials. It's focused on transforming the lives of patients by discovering, designing, and developing regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences. Its product includes SkinTE used for repair, reconstruction, replacement, or regeneration of the skin in patients who have or require treatment of acute and chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts. It operates in two segments: the regenerative medicine business segment and the contract research segment.

Regenetp (STU:NJT) Headlines

No Headlines